Eric Keller, J.D.
Chief Executive Officer, Founder & Chairman
Eric Keller is a proven business and legal executive with nearly 30 years of experience in life sciences-based companies. In addition to his role as Founder and CEO of Response Pharmaceutical, he is the Founder and CEO of Redux Therapeutics, a therapeutic asset acquisition and development company, as well as Response Pharmaceuticals sister company, Retension Pharmaceuticals.
Paul Sweetnam, Ph.D.
Chief Scientific Officer & Co-Founder
Paul has over 25 years of experience in senior scientific and management roles in pharmaceuticals and biotechnology. Notably, he led the discovery of RDX-002 at Surface Logix, Inc. and contributed to transitioning eight candidate molecules into clinical development at Bayer Healthcare, including Nexavar.
William Sasiela, Ph.D.
Chief Medical Officer
Bill has focused his career on developing therapeutics combating cardiometabolic diseases. During his 25 year tenure in the biopharmaceutical and biotech industry, Bill has played crucial roles in developing groundbreaking cardiovascular and metabolic drugs, including Lipitor, Juxtapid, Praluent, Evkeeza, and Nexletol. His expertise in development of cardiometabolic therapies is widely recognized in the industry.
Craig M. Audet, Ph.D.
Chief Regulatory Officer
Craig held leadership roles at Pfizer, Sanofi, Arena Pharmaceuticals, and Evofem Biosciences, and has 36+ years’ experience in pharmaceuticals and medical devices. Craig has extensive expertise in regulatory strategy across all stages of development and has been involved in development and commercialization of numerous therapeutics. He holds degrees from Boston College and Walden University.
Management
Liam Brenner, M.B.A.
Chief Financial Officer
Liam has over 20 years of experience supporting high-growth and early-stage companies in healthcare and technology. As a CFO Partner at TechCXO, he has led finance functions for telehealth and life sciences ventures, and previously served as Head of Finance at Haven — the healthcare initiative founded by Amazon, Berkshire Hathaway, and JP Morgan Chase. He began his career at Ernst & Young covering pre-IPO and venture-backed companies. Liam holds an MBA and BS in Accounting from Babson College.
Sabine Bisson. Ph.D.
Chief Operating Officer
Sabine has held key positions in small and growing biotech companies, overseeing development and partnership activities across the R&D lifecycle. With nearly 20 years of strategic and operational leadership, she brings extensive cross-functional experience at the program, portfolio and corporate level. She was instrumental in the development of several lifesaving therapeutics, including the CV metabolism drug Praluent® and the Immuno-Oncology agent Libtayo® among others. Sabine earned her Ph.D. in Canada and completed her postdoctoral training as a Howard Hughes Scholar at UCSF.